Background: The development and risk potential of hypertension-induced left ventricular (LV) hypertrophy has been well described in epidemiological studies. Regression of LV hypertrophy reduces cardiovascular morbidity and mortality. However, the best treatment strategy is still debated, as well as the appropriate blood pressure target in these patients.
Objective: We here review the treatment of LV hypertrophy and the potential benefit on clinical outcomes, against a background of the epidemiology and pathophysiology.
Results: Both hemodynamic and non-hemodynamic mechanisms contribute to hypertensive LV hypertrophy, which is characterized by an inappropriate myocardial fibrosis. Stringent blood pressure control reduces LV hypertrophy. Blockers of the renin-angiotensin-aldosterone system may have valuable effects on cardiac and electrophysiological remodelling beyond the effects of blood pressure reduction. Thus, they represent a cornerstone in the treatment of hypertensive LV hypertrophy, but most often other antihypertensive drug classes need to be added. Current guidelines indicate a blood pressure target in most patients with hypertensive LV hypertrophy of 120–130/80 mmHg.
Conclusions: LV hypertrophy and myocardial fibrosis are important characteristics of hypertensive heart disease and associated with untoward prognosis. Regression of LV hypertrophy reduces cardiovascular morbidity and mortality. New drugs under development may add additional benefit.
Keywords: Cardiac hypertrophy, fibrosis, hypertensive heart disease, hypertension, renin-angiotensin-aldosterone system, treatment.
Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design The Effect of Statins on Postprandial Lipemia
Current Drug Targets Mechanistic View of Renal Protective Action of Calcium Channel Blockade
Current Hypertension Reviews Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology Editorial (Thematic Issue: Novel Oral Anticoagulants; “All that Glitters is not Gold, or is it?”)
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Perioperative Heart-Brain Axis Protection in Obese Surgical Patients: The Nutrigenomic Approach
Current Medicinal Chemistry Physical Activity, Insulin Action, and Diabetes Prevention and Control
Current Diabetes Reviews Treatment of Disability in Peripheral Arterial Disease: New Drugs
Current Drug Targets - Cardiovascular & Hematological Disorders Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris
Current Drug Safety Issues and Progress in Isolation of Susceptibility Genes of Essential Hypertension
Current Hypertension Reviews A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application
Current Drug Targets Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation
Current Vascular Pharmacology Obesity-Associated Hypertension in Childhood: A New Epidemic Problem
Current Hypertension Reviews Does Perioperative Hemoglobin A1c Level Affect the Incidence, Pattern and Mortality of Lower Extremity Amputation?
Current Vascular Pharmacology Interleukin-1 and Occlusive Arterial Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry